Literature DB >> 26690726

Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.

S V Wang1, P Verpillat2, J A Rassen3, A Patrick3, E M Garry4, D B Bartels2,5.   

Abstract

The scientific community and decision-makers are increasingly concerned about transparency and reproducibility of epidemiologic studies using longitudinal healthcare databases. We explored the extent to which published pharmacoepidemiologic studies using commercially available databases could be reproduced by other investigators. We identified a nonsystematic sample of 38 descriptive or comparative safety/effectiveness cohort studies. Seven studies were excluded from reproduction, five because of violation of fundamental design principles, and two because of grossly inadequate reporting. In the remaining studies, >1,000 patient characteristics and measures of association were reproduced with a high degree of accuracy (median differences between original and reproduction <2% and <0.1). An essential component of transparent and reproducible research with healthcare databases is more complete reporting of study implementation. Once reproducibility is achieved, the conversation can be elevated to assess whether suboptimal design choices led to avoidable bias and whether findings are replicable in other data sources.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2016        PMID: 26690726      PMCID: PMC7833029          DOI: 10.1002/cpt.329

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  32 in total

1.  Design considerations, architecture, and use of the Mini-Sentinel distributed data system.

Authors:  Lesley H Curtis; Mark G Weiner; Denise M Boudreau; William O Cooper; Gregory W Daniel; Vinit P Nair; Marsha A Raebel; Nicolas U Beaulieu; Robert Rosofsky; Tiffany S Woodworth; Jeffrey S Brown
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

2.  Registration of observational studies: is it time?

Authors:  Rebecca J Williams; Tony Tse; William R Harlan; Deborah A Zarin
Journal:  CMAJ       Date:  2010-07-19       Impact factor: 8.262

3.  GRACE principles: recognizing high-quality observational studies of comparative effectiveness.

Authors:  Nancy A Dreyer; Sebastian Schneeweiss; Barbara J McNeil; Marc L Berger; Alec M Walker; Daniel A Ollendorf; Richard E Gliklich
Journal:  Am J Manag Care       Date:  2010-06       Impact factor: 2.229

4.  Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.

Authors:  Michael L Johnson; William Crown; Bradley C Martin; Colin R Dormuth; Uwe Siebert
Journal:  Value Health       Date:  2009-09-29       Impact factor: 5.725

5.  Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.

Authors:  Hoa Van Le; Kathleen J Beach; Gregory Powell; Ed Pattishall; Patrick Ryan; Robertino M Mera
Journal:  Stat Methods Med Res       Date:  2011-06-16       Impact factor: 3.021

6.  Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.

Authors:  Sengwee Toh; Meghan A Baker; Jeffrey S Brown; Cynthia Kornegay; Richard Platt
Journal:  JAMA Intern Med       Date:  2013-05-13       Impact factor: 21.873

7.  A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Authors:  Joshua J Gagne; Shirley V Wang; Jeremy A Rassen; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-04-30       Impact factor: 2.890

8.  Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Robert J Glynn; Yuka Kiyota; Raisa Levin; Helen Mogun; Jerry Avorn
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

9.  Setting the RECORD straight: developing a guideline for the REporting of studies Conducted using Observational Routinely collected Data.

Authors:  Sinéad M Langan; Eric I Benchimol; Astrid Guttmann; David Moher; Irene Petersen; Liam Smeeth; Henrik Toft Sørensen; Fiona Stanley; Erik Von Elm
Journal:  Clin Epidemiol       Date:  2013-02-07       Impact factor: 4.790

10.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Authors:  J J Gagne; R J Glynn; J A Rassen; A M Walker; G W Daniel; G Sridhar; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

View more
  52 in total

1.  Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.

Authors:  Elisabetta Patorno; Sebastian Schneeweiss; Chandrasekar Gopalakrishnan; David Martin; Jessica M Franklin
Journal:  Diabetes Care       Date:  2019-06-25       Impact factor: 19.112

2.  Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety.

Authors:  Shirley V Wang; Olga V Patterson; Joshua J Gagne; Jeffrey S Brown; Robert Ball; Pall Jonsson; Adam Wright; Li Zhou; Wim Goettsch; Andrew Bate
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

3.  Prediction of Cardiovascular Risk to Guide Primary Prevention.

Authors:  Gregory D Curfman
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

Review 4.  Clinical Research Informatics: Supporting the Research Study Lifecycle.

Authors:  S B Johnson
Journal:  Yearb Med Inform       Date:  2017-09-11

5.  Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Authors:  Michael Fralick; Sarah K Chen; Elisabetta Patorno; Seoyoung C Kim
Journal:  Ann Intern Med       Date:  2020-01-14       Impact factor: 25.391

Review 6.  Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.

Authors:  Elisabetta Patorno; Sebastian Schneeweiss; Shirley V Wang
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

7.  Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.

Authors:  Jing Luo; Nazleen F Khan; Thomas Manetti; Jim Rose; Ani Kaloghlian; Balu Gadhe; Sachin H Jain; Joshua J Gagne; Aaron S Kesselheim
Journal:  JAMA       Date:  2019-01-29       Impact factor: 56.272

8.  Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

Authors:  Michael Fralick; Chana A Sacks; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

9.  Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Authors:  Elisabetta Patorno; Ajinkya Pawar; Jessica M Franklin; Mehdi Najafzadeh; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Steven Sambevski; Lily G Bessette; Adrian J Santiago Ortiz; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Circulation       Date:  2019-04-08       Impact factor: 29.690

10.  Use of Health Care Databases to Support Supplemental Indications of Approved Medications.

Authors:  Michael Fralick; Aaron S Kesselheim; Jerry Avorn; Sebastian Schneeweiss
Journal:  JAMA Intern Med       Date:  2018-01-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.